Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.85 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | STAT1 | P42224 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ACP1 | P24666 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229810 | 0.92 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL31041 | 0.91 | NPC1 (0.93) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL1842324 | 0.89 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL2792307 | 0.87 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| Hydrochloric Acid SCHEMBL1844043 | 0.87 | NPC1 (0.97) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL2792818 | 0.85 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL2791120 | 0.85 | RAB9A (0.74) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL2816736 | 0.84 | RAB9A (0.72) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL6905516 | 0.84 | RAB9A (0.72) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A | |
| SCHEMBL27634788 | 0.83 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2ADORA1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| US-6900219-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1513534-A2 | COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030220356-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003084544-A2 | COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220356-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | NPC1 6/4885RAB9A 2138/4885SMN1; SMN2 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.